Navigation Links
Mindray Announces Third Quarter 2013 Financial Results
Date:11/4/2013

SHENZHEN, China, Nov. 4, 2013 /PRNewswire/ -- Mindray Medical International Limited (NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide, announced today its selected unaudited financial results for the third quarter ended September 30, 2013.

Highlights for Third Quarter 2013

  • Net revenues increased 15.3% year-over-year to $296.3 million. International sales grew 17.9% and China sales rose 12.1% compared to the same period of last year.
  • Western Europe recorded a year-over-year net revenue growth of more than 25%. Certain key countries in the emerging markets also continued to perform well.
  • Reagent sales contributed 40.2% to the IVD segment, up from 37.4% in the same period last year and 36.6% in the previous quarter.
  • Non-GAAP net income increased 14.5% to $57.4 million from the same period of last year.
  • The cash conversion cycle was 91 days, compared to 106 days in the same period last year, primarily due to better control on receivable collections.
  • Mindray introduced its very first chemiluminescence immunoassay product, the CL-2000i, with several reagents.
  • Mindray completed two acquisitions during the quarter – Zonare Medical Systems, Inc., a US ultrasound company, and Ulco Medical Pty. Ltd., an Australia-based former distributor of Mindray.
  • "In the third quarter, we reported solid top-line growth. We are particularly happy with our continued strong sales performance in Western Europe. Certain key emerging markets also continued to do well, although demand in some countries remained soft due to external factors. In China, the recent weak market sentiment in the healthcare sector has caused some delays in purchasing activities in the third quarter. However, the industry fundamentals remain solid," said Mr. Li Xiting, Mindray's President and Co-Chief Executive Officer. "Reagent sales continued to climb this quarter, highlighting our success in ramping up this recurring IVD revenue. We are also excited to launch our first-generation immunoassay product, which further strengthened our IVD product offerings."

    SUMMARY – Third quarter 2013(in $ millions, except per-share data)

    Three Months EndedSeptember 302013

    2012

    % chgNet Revenues

    296.3

    257.1

    15.3%Net Revenues Generated in China

    132.0

    117.7

    12.1%Net Revenues Generated in International Markets

    164.3

    139.4

    17.9%Gross Profit

    165.1

    144.0

    14.7%Non-GAAP Gross Profit

    167.2

    145.2

    15.2%Operating Income

    50.5

    39.1

    29.3%Non-GAAP Operating Income

    57.4

    53.5

    7.4%EBITDA

    64.7

    48.3

    33.8%Net Income

    30.1

    35.8

    -15.9%Non-GAAP Net Income

    57.4

    50.1

    14.5%Diluted EPS

    0.25

    0.30

    -16.8%Non-GAAP Diluted EPS

    0.47

    0.42

    13.3%Net RevenuesMindray reported net revenues of $296.3 million for the third quarter of 2013, a 15.3% increase from $257.1 million in the third quarter of 2012.

  • Net revenues generated in China increased 12.1% to $132.0 million from $117.7 million in the third quarter of 2012.
  • Net revenues generated in the international markets increased 17.9% to $164.3 million from $139.4 million in the third quarter of 2012.
  • Performance by SegmentPatient Monitoring & Life Support Products: Net revenues in this segment increased 6.2% to $110.3 million from $103.8 million in the third quarter of 2012, contributing 37.2% to total net revenues in the third quarter of 2013.

    In-Vitro Diagnostic Products: Net revenues in this segment increased 14.2% to $83.0 million from $72.6 million in the third quarter of 2012, contributing 28.0% to total net revenues in the third quarter of 2013. Reagents sales represented 40.2% of this segment's net revenues.

    Medical Imaging Systems: Net revenues in this segment increased 26.7% to $77.1 million from $60.9 million in the third quarter of 2012, contributing 26.0% to total net revenues in the third quarter of 2013.

    Others: Net revenues increased 31.2% to $25.9 million from $19.8 million in the third quarter of 2012, contributing 8.8% to total net revenues in the third quarter of 2013. Other net revenues mainly include sales from the orthopedics business, service revenues from extended warranties, sales of accessories and repair service revenues for post-warranty period.

    Gross MarginThird quarter 2013 gross profit was $165.1 million, a 14.7% increase from $144.0 million in the third quarter of 2012. Third quarter 2013 non-GAAP gross profit was $167.2 million, a 15.2% increase from $145.2 million in the third quarter of 2012. Third quarter 2013 gross margin was 55.7% compared to 56.0% in the third quarter of 2012 and 57.5% in the second quarter of 2013. Non-GAAP gross margin was 56.4% compared to 56.5% in the third quarter of 2012 and 58.2% in the second quarter of 2013.

    Operating ExpensesSelling expenses in the third quarter of 2013 were $57.5 million, or 19.4% of total net revenues, compared to 18.5% in the third quarter of 2012 and 17.8% in the second quarter of 2013. Non-GAAP selling expenses were $54.2 million, or 18.3% of total net revenues, compared to 17.8% in the third quarter of 2012 and 17.0% in the second quarter of 2013.

    General and administrative expenses for the third quarter of 2013 were $25.5 million, or 8.6% of total net revenues, lower than 13.2% in the third quarter of 2012 and 8.7% in the second quarter of 2013. Non-GAAP general and administrative expenses for the third quarter of 2013 were $25.0 million, or 8.4% of total net revenues, lower than 9.2% in the third quarter of 2012 and 8.5% in the second quarter of 2013.

    Research and development expenses for the third quarter of 2013 were $31.6 million, or 10.7% of total net revenues, higher than 9.0% in the third quarter of 2012 and 9.3% in the second quarter of 2013. Non-GAAP research and development expenses for the third quarter of 2013 were $30.6 million, or 10.3% of total net revenues, compared to 8.6% in the third quarter of 2012 and 8.9% in the second quarter of 2013.

    Total share-based compensation expenses, which were allocated to cost of revenues and related operating expenses, were $2.9 million in the third quarter of 2013, lower than $3.1 million in the third quarter of 2012 and $3.2 million in the second quarter of 2013.

    Operating income was $50.5 million in the third quarter of 2013, a 29.3% increase from $39.1 million in the third quarter of 2012. Non-GAAP operating income in the third quarter of 2013 was $57.4 million, a 7.4% increase from $53.5 million in the third quarter of 2012. Operating margin was 17.1% in the third quarter of 2013, higher than 15.2% in the third quarter of 2012 but below 21.7% in the second quarter of 2013. Non-GAAP operating margin was 19.4% in the third quarter of 2013 compared to 20.8% in the third quarter of 2012 and 23.8% in the second quarter of 2013.

    Earnings Before Interest, Taxes, Depreciation and Amortization ("EBITDA")Third quarter 2013 EBITDA increased 33.8% year-over-year to $64.7 million from $48.3 million in the third quarter of 2012.

    Net IncomeThird quarter 2013 net income declined 15.9% year-over-year to $30.1 million from $35.8 million in the third quarter of 2012. Third quarter 2013 non-GAAP net income increased 14.5% year-over-year to $57.4 million from $50.1 million in the third quarter of 2012. Net margin was 10.1% in the third quarter of 2013 compared to 13.9% in the third quarter of 2012 and 20.2% in the second quarter of 2013. Non-GAAP net margin was 19.4% in the third quarter of 2013, compared to 19.5% in the third quarter of 2012 and 22.2% in the second quarter of 2013.

    Third quarter 2013 basic and diluted earnings per share were both $0.25, compared to $0.31 and $0.30 respectively in the third quarter of 2012. Third quarter 2013 basic and diluted non-GAAP earnings per share were $0.48 and $0.47 respectively, compared to $0.43 and $0.42 in the third quarter of 2012. Shares used in the computation of diluted earnings per share for the third quarter 2013 were 121.2 million.

    Other Select DataAccounts receivable turnover days were 56 days in the third quarter of 2013, improved from 66 days in the third quarter of 2012 and compared to 52 days in the second quarter of 2013. Inventory turnover days were 94 days in the third quarter of 2013, shorter than 100 days in the third quarter of 2012 and compared to 88 days in the second quarter of 2013. Accounts payable turnover days were 59 days in the third quarter of 2013, compared to 60 days in the third quarter of 2012 and 54 days in the second quarter of 2013. Mindray calculates the above working capital turnover days using the average of the beginning and ending net balances of the quarter.

    As of September 30, 2013, the company had $1 billion in cash and cash equivalents as well as short-term investments, compared to $958.5 million as of June 30, 2013. Net cash generated by operating activities and net cash outflow for capital expenditures during the quarter were $67.1 million and $26.9 million respectively.

    As of September 30, 2013, the company had around 7,860 employees.

    Business Outlook for Full Year 2013Mindray revises its full year 2013 net revenues guidance and now forecasts at least 13% growth over its full year 2012 net revenues.

    The company also updates its full year 2013 non-GAAP net income guidance and projects at least 11% growth over its non-GAAP net income for the full year of 2012. This guidance excludes any tax benefit related to the National Key Software Enterprise status and assumes a corporate income tax rate of 15% for the Shenzhen subsidiary.

    The company expects its capital expenditure for full year 2013 to be around $100 million.

    The company's practice is to provide guidance on a full year basis only. This forecast reflects Mindray's current and preliminary views, which are subject to change.

    "We are revising our financial guidance for 2013, primarily due to the enduring hospital purchase slowdown in China. In other geographies, we expect some countries to perform well in the emerging markets, but political and currency issues will affect other areas. For the developed markets, we are confident about our expansion in Western Europe and expect the North American business will stabilize," commented Mr. Cheng Minghe, Mindray's Co-Chief Executive Officer and Chief Strategic Officer. "Overall, we remain upbeat about the long-term prospects of Mindray. We will continue to work hard to increase our worldwide market penetration, optimize our global operations and seek promising external growth opportunities."

    Conference Call InformationMindray's management will hold an earnings conference call at 8:00 AM on November 5, 2013 U.S. Eastern Time (9:00 PM on November 5, 2013 Beijing/Hong Kong Time).

    Dial-in details for the earnings conference call are as follows:

    International Toll Free:United States:

    +1-866-519-4004Hong Kong:

    800-930-346China Landline:

    800-819-0121Local dial-in numbers:United States:

    +1-845-675-0437Hong Kong:

    +852-2475-0994 China Mobile:

    400-620-8038Passcode for all regions:

    MindrayA replay of the conference call may be accessed by phone at the following numbers until November 20, 2013.

    U.S. Toll Free:

    +1-855-452-5696International:

    +1-646-254-3697Passcode:

    86589814Additionally, a live and archived webcast of this conference call will be available on the Investor Relations section of Mindray's website at: http://ir.mindray.com/.

    Use of Non-GAAP Financial Measures Mindray provides gross profit, selling expenses, general and administrative expenses, R&D expenses, operating income, net income and earnings per share on a non-GAAP basis that excludes share-based compensation expense, acquired intangible assets amortization expense, dispute charges and withholding tax for intra-group fund transfer, all net of related tax impact, as well as EBITDA to enable investors to better assess the company's operating performance. The non-GAAP measures described by the company are reconciled to the corresponding GAAP measure in the exhibit below titled "Reconciliations of non-GAAP results of operations measures to the nearest comparable GAAP measures".

    The company has reported for the third quarter of 2013 and provided guidance for full year 2013 earnings on a non-GAAP basis. Each of the terms as used by the company is defined as follows:

  • Non-GAAP gross profit represents gross profit reported in accordance with GAAP, adjusted for the effects of share-based compensation and amortization of acquired intangible assets.
  • Non-GAAP operating income represents operating income reported in accordance with GAAP, adjusted for the effects of share-based compensation, amortization of acquired intangible assets and dispute charges.
  • Non-GAAP selling expenses represent selling expenses reported in accordance with GAAP, adjusted for the effects of share-based compensation and amortization of acquired intangible assets.
  • Non-GAAP general and administrative expenses represent general and administrative expenses reported in accordance with GAAP, adjusted for the effects of share-based compensation and dispute charges.
  • Non-GAAP research and development expenses represent research and development expenses reported in accordance with GAAP, adjusted for the effects of share-based compensation.
  • Non-GAAP net income represents net income reported in accordance with GAAP, adjusted for the effects of share-based compensation, amortization of acquired intangible assets, dispute charges and withholding tax for intra-group transfer, all net of related tax impact.
  • Non-GAAP earnings per share represents non-GAAP net income divided by the number of shares used in computing basic and diluted earnings per share in accordance with GAAP, and excludes the impact of the declared dividends for the basic calculation.
  • EBITDA represents net income reported in accordance with GAAP, adjusted for the effect of interest income and expenses, provision of income taxes, depreciation and amortization.
  • The company computes its non-GAAP financial measures using the same consistent method from quarter to quarter. The company notes that these measures may not be calculated on the same basis of similar measures used by other companies. Readers are cautioned not to view non-GAAP results on a stand-alone basis or as a substitute for results under GAAP, or as being comparable to results reported or forecasted by other companies, and should refer to the reconciliation of GAAP results with non-GAAP results for the three and nine months ended September 30, 2012 and 2013, respectively, in the attached financial information.

    Cautionary Note Regarding Forward-Looking StatementsThis press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including, without limitation, statements about Mindray's anticipated net revenues, non-GAAP net income and capital expenditure for 2013, our assumption of a corporate income tax rate of 15% applicable to the Shenzhen subsidiary, statements that the industry fundamentals remain solid, that we are also excited to launch our first-generation immunoassay products, which further strengthened our IVD products offerings, Mindray's revised full year revenue guidance, statement that Mindray now forecasts at least 13% growth over its full year 2012 net revenues, our updated full year 2013 non-GAAP net income guidance, our projections of at least 11% growth over our non-GAAP net income for the full year of 2012, statement that we expect capital expenditure for full year 2013 to be around USD100million, statement about the enduring hospital purchase slow down in China, statement that we expect some countries to perform well in the emerging markets, but political and currency issues will affect other areas, our confidence about our expansion in Western Europe, our expectation that North American business will stabilize, statement that we remain upbeat about the long-term prospects of Mindray and statement that we will continue to work hard to increase our worldwide market penetration, optimize our global operations and seek promising external growth opportunities,  are forward-looking statements. Readers are cautioned that these forward-looking statements are only predictions and may differ materially from actual results due to a variety of factors, including, without limitation, the growth and expected growth of the medical device market in China and internationally; relevant government policies and regulations relating to the medical device industry; market acceptance of our products; our expectations regarding demand for our products; our ability to expand our production, our sales and distribution network and other aspects of our operations; our ability to stay abreast of market trends and technological advances; our ability to effectively protect our intellectual property rights and not infringe on the intellectual property rights of others; our ability to settle disputes with our customers and suppliers; competition in the medical device industry in China and internationally; and general economic and business conditions in the countries in which we operate. For a discussion of other important factors that could adversely affect our business, financial condition, results of operations and prospects, see "Risk Factors" beginning on page 5 of our annual report on Form 20-F which was filed with the Securities and Exchange Commission on April 8, 2013. Our results of operations for the third quarter as of September 30, 2013 are not necessarily indicative of our operating results for any future periods. The financial information contained in this release should be read in conjunction with the consolidated financial statements and notes thereto included in our public filings with the Securities and Exchange Commission. Any projections in this release are based on limited information currently available to us, which is subject to change. Although such projections and the factors influencing them will likely change, we will not necessarily update the information. Such information speaks only as of the date of this release.

    All references to "shares" are to our ordinary shares, which are divided into two classes, Class A and Class B. Each of our American Depositary Shares, which trade on the New York Stock Exchange, represents one Class A ordinary share.

    About Mindray We are a leading developer, manufacturer and marketer of medical devices worldwide. We maintain our global headquarters in Shenzhen, China, U.S. headquarters in Mahwah, New Jersey and multiple sales offices in major international markets. From our main manufacturing and engineering base in China, we supply through our worldwide distribution network a broad range of products across three primary business segments, namely patient monitoring and life support, in-vitro diagnostic, and medical imaging systems. For more information, please visit http://ir.mindray.com.

    For investor and media inquiries, please contact:

    In China:
    Cathy Gao
    Mindray Medical International Limited
    Tel: +86-755-8188-8023
    Email: cathy.gao@mindray.com

    In the U.S:
    Hoki Luk
    Western Bridge, LLC
    Tel: +1-646-808-9150
    Email: hoki.luk@westernbridgegroup.com

     Exhibit 1MINDRAY MEDICAL INTERNATIONAL LIMITEDCONDENSED CONSOLIDATED BALANCE SHEETS(Dollars in thousands)As of December 31, 2012As of September 30, 2013 US$  US$  (Note 1)  (unaudited) ASSETSCurrent assets:Cash and cash equivalents

    247,859200,018Restricted cash and restricted investment (Note 2)

    21,528568Short-term investments 

    615,003825,802Accounts receivable, net

    185,701179,290Inventories

    110,099143,733Value added tax receivables

    7,42724,460Other receivables

    15,70435,267Prepayments and deposits

    11,08117,311Deferred tax assets,net

    6,4438,290Total current assets

    1,220,8451,434,739Restricted cash, non-current (Note 2)

    -18,000Other assets

    10,81111,799Accounts receivables, net, non-current

    2,1721,566Advances for purchase of plant and equipment

    3,0097,829Property, plant and equipment, net

    268,010299,790Land use rights, net 

    56,92159,307Intangible assets, net

    132,334182,040Goodwill

    163,016242,540Total assets

    1,857,1182,257,610LIABILITIES AND SHAREHOLDERS' EQUITYCurrent liabilities:Short-term bank loans

    85,100100,049Notes payable

    8,6979,424Accounts payable

    53,24477,847Advances from customers

    17,55026,107Salaries payable

    69,91970,823Other payables

    108,528108,690Purchase consideration payable

    20,35424,800Income taxes payable

    30,30539,226Other taxes payable

    8,89410,558Total current liabilities

    402,591467,524Long-term bank loan

    50,039214,856Other long-term liabilities

    4,0046,990Deferred tax liabilities, net

    23,36942,166Total liabilities

    480,003731,536Commitments and contingenciesShareholders' equity:Ordinary shares

    1515Additional paid-in capital

    514,280540,831Retained earnings

    699,992790,460Accumulated other comprehensive income

    116,556137,358Total shareholders' equity

    1,330,8431,468,664Non-controlling interests

    46,27257,410Total equity

    1,377,1151,526,074Total liabilities and equity

    1,857,1182,257,610(1) Financial information is extracted from the audited financial statements included in the Company's 2012 annual reports on Form 20-F.(2) Restricted cash and restricted investment are mainly those purchase consideration in connection with our acquisition being held on escrow accounts. Exhibit 2MINDRAY MEDICAL INTERNATIONAL LIMITEDCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(Dollars in thousands, except for share and per share data)Three months ended September 30,Nine months ended September 30,2012201320122013US$ US$ US$ US$ (unaudited) (unaudited) (unaudited) (unaudited) Net revenues- China117,721132,007324,855390,754- International 139,370164,311419,083454,818Net revenues257,091296,318743,938845,572Cost of revenues (113,134)(131,180)(326,034)(364,886)Gross profit143,957165,138417,904480,686Selling expenses (47,628)(57,499)(135,116)(159,215)General and administrative expenses (34,036)(25,530)(79,761)(78,743)Research and development expenses (23,222)(31,573)(71,376)(86,474)Income from operations39,07150,536131,651156,254Other income, net4693331,442832Interest income7,14710,03422,84526,261Interest expense(1,087)(1,742)(3,065)(4,185)Income before income taxes and non-controlling interests45,60059,161152,873179,162Provision for income taxes(9,108)(27,935)(27,474)(25,744)Net income 36,49231,226125,399153,418Less: Net income attributable to non-controlling interests(726)(1,162)(1,039)(3,880)Net income attributable to the Company35,76630,064124,360149,538Basic earnings per share0.310.251.071.26Diluted earnings per share0.300.251.041.24Shares used in the computation of:Basic earnings per share117,083,942119,142,051116,550,514118,616,515Diluted earnings per share119,895,832121,162,145119,571,324120,945,344 

     Exhibit 3MINDRAY MEDICAL INTERNATIONAL LIMITEDCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(Dollars in thousands)Three months ended September 30,Nine months ended September 30,2012201320122013 US$  US$  US$  US$  (unaudited)  (unaudited)  (unaudited)  (unaudited) Cash flow from operating activities:  Net income

    36,49231,226125,399153,418  Adjustments to reconcile net income to net cash provided by operating activities

    13,38718,77549,66751,104  Changes in current assets and liabilities, net of effects of acquisitions

    9,41817,0965,707(18,800)Net cash provided by operating activities 59,29767,097180,773185,722Cash flow from investing activities:Acquisition cost of subsidiaries, net of cash received 

    (28,749)(87,533)(31,488)(105,018)Capital expenditure

    (14,409)(26,939)(47,244)(67,179)(Increase) decrease in restricted cash and restricted investment 

    -(18,304)-2,960Proceeds from sale of short-term investments

    -187,471144,395591,808Increase in short-term investments and changes in other investing activities

    (110,039)(244,626)(235,528)(794,145)Net cash used in investing activities(153,197)(189,931)(169,865)(371,574)Cash flow from financing activities:Repayment of bank loans

    ---(35,000)Proceeds from bank loans

    -120,00052,000215,000Dividend paid

    --(46,401)(59,070)Proceeds from exercise of options

    8,4916,74822,62915,600Cash contribution from non-controlling interest

    --506-Net cash provided by financing activities8,491126,74828,734136,530Net (decrease) increase in cash and cash equivalents(85,409)3,91439,642(49,322)Cash and cash equivalents, beginning of period

    247,985195,373124,311247,859Effect of exchange rate changes on cash

    1,9237315461,481Cash and cash equivalents, end of period164,499200,018164,499200,018 Exhibit 4
    MINDRAY MEDICAL INTERNATIONAL LIMITED
    RECONCILIATIONS OF NON-GAAP RESULTS OF OPERATIONS MEASURES TO THE NEAREST COMPARABLE GAAP MEASURES
    (Dollars in thousands, except for share and per share data)Three months ended September 30,Nine months ended September 30,2012201320122013(unaudited)(unaudited)(unaudited)(unaudited) US$  US$  US$  US$ Non-GAAP net income attributable to the Company50,13557,412150,029190,220Non-GAAP net margin19.5%19.4%20.2%22.5%Amortization of acquired intangible assets(1,630)(3,948)(4,894)(9,752)Withholding tax for intra-group fund transfer-(20,804)-(20,804)Deferred tax impact related to acquired intangible assets59353177768Dispute charges(9,700)-(9,700)-Share-based compensation(3,098)(2,949)(11,252)(10,894)GAAP net income attributable to the Company35,76630,064124,360149,538GAAP net margin13.9%10.1%16.7%17.7%Non-GAAP basic earnings per share0.430.481.291.60Non-GAAP diluted earnings per share0.420.471.251.57GAAP basic earnings per share0.310.251.071.26GAAP diluted earnings per share0.300.251.041.24 Shares used in computation of:  Basic earnings per share 117,083,942119,142,051116,550,514118,616,515 Diluted earnings per share 119,895,832121,162,145119,571,324120,945,344Non-GAAP operating income53,49957,433157,497176,900Non-GAAP operating margin20.8%19.4%21.2%20.9%Amortization of acquired intangible assets(1,630)(3,948)(4,894)(9,752)Dispute charges(9,700)-(9,700)-Share-based compensation(3,098)(2,949)(11,252)(10,894)GAAP operating income39,07150,536131,651156,254GAAP operating margin15.2%17.1%17.7%18.5%Non-GAAP gross profit145,171167,222421,416486,641Non-GAAP gross margin56.5%56.4%56.6%57.6%Amortization of acquired intangible assets (963)(1,888)(2,889)(5,415)Share-based compensation(251)(196)(623)(540)GAAP gross profit143,957165,138417,904480,686GAAP gross margin56.0%55.7%56.2%56.8%Non-GAAP selling expenses(45,786)(54,182)(129,624)(151,279)Non-GAAP as % of total revenues17.8%18.3%17.4%17.9%Amortization of acquired intangible assets (667)(2,060)(2,005)(4,337)Share-based compensation(1,175)(1,257)(3,487)(3,599)GAAP selling expenses(47,628)(57,499)(135,116)(159,215)GAAP as % of total revenues18.5%19.4%18.2%18.8%Non-GAAP general and administrative expenses(23,735)(25,007)(66,153)(75,188)Non-GAAP as % of total revenues9.2%8.4%8.9%8.9%Dispute charges(9,700)-(9,700)-Share-based compensation(601)(523)(3,908)(3,555)GAAP general and administrative expenses(34,036)(25,530)(79,761)(78,743)GAAP as % of total revenues13.2%8.6%10.7%9.3%Non-GAAP research and development expenses(22,151)(30,600)(68,142)(83,274)Non-GAAP as % of total revenues8.6%10.3%9.2%9.8%Share-based compensation(1,071)(973)(3,234)(3,200)GAAP research and development expenses(23,222)(31,573)(71,376)(86,474)GAAP as % of total revenues9.0%10.7%9.6%10.2% 

     Exhibit 5
    MINDRAY MEDICAL INTERNATIONAL LIMITED
    RECONCILIATION OF GAAP NET INCOME TO EARNINGS BEFORE INTEREST, TAXES, DEPRECIATION AND AMORTIZATION
    (Dollars in thousands)Three months ended September 30,Nine months ended September 30,2012201320122013US$US$US$US$(unaudited)(unaudited)(unaudited)(unaudited)GAAP net income attributable to the Company

    $

    35,76630,064124,360149,538Interest income(7,147)(10,034)(22,845)(26,261)Interest expense1,0871,7423,0654,185Provision for income taxes9,10827,93527,47425,744Earnings before interest and taxes ("EBIT")38,81449,707132,054153,206Depreciation6,5578,80420,59824,514Amortization2,9636,1528,75515,649Earnings before interest,taxes,depreciation and amortization ("EBITDA")48,33464,663161,407193,369 


    '/>"/>
    SOURCE Mindray Medical International Limited
    Copyright©2012 PR Newswire.
    All rights reserved


    Related medicine technology :

    1. Mindray Files Annual Report on Form 20-F with the U.S. Securities and Exchange Commission
    2. Mindray Medical to Acquire Controlling Stake in Hangzhou Optcla Medical Instrument
    3. Mindray Announces First Quarter 2012 Financial Results
    4. Mindray Medical to Present at AACC Clinical Lab Expo 2012
    5. Mindray Medical Completes Acquisition of Dragonbios Orthopedics Business
    6. Mindray to Report Second Quarter 2012 Financial Results on August 6, 2012
    7. Mindray Announces Second Quarter 2012 Financial Results
    8. Mindray Medical to Participate in MEDICA 2012 in Dusseldorf, Germany
    9. Mindray Medical Announces Top Management Change
    10. Mindray DS USA, Inc. has Initiated a Voluntary Recall Affecting the A3/A5 Anesthesia Delivery System
    11. Mindray to Showcase Enhancements to DC-8 Ultrasound System at RSNA
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/12/2016)... 2016  This month,s issue of the Journal ... an in-depth look at various causes and consequences associated with rising ... spending, which has generated significant public outrage and calls ... Laura E. Happe , PharmD, MPH. --> ... MPH. --> In 2014 prescription drug spending ...
    (Date:2/12/2016)... -- Innophos Holdings, Inc. (NASDAQ: IPHS ), a leading international ... it will host a live conference call on Tuesday, February ... quarter and full year 2015 results. ... quarter and full year results will be issued on Monday, ... --> --> The conference call can be ...
    (Date:2/12/2016)... , Feb. 12, 2016   HeartWare International, Inc ... call and webcast to discuss its financial results for ... on Thursday, February 25, 2016 at 8:00 a.m. ET. ... to the conference call and webcast.  On the conference ... results, highlights from the fourth quarter and business outlook.   ...
    Breaking Medicine Technology:
    (Date:2/12/2016)... ... February 12, 2016 , ... As a former television executive, owner Tal Rabinowitz ... no time to decompress, Rabinowitz found herself drawn to a casual meditation class while ... on her life, implementing a 20-minute-per-day meditation practice with her team. After her tenure ...
    (Date:2/12/2016)... ... February 12, 2016 , ... Itopia, a leader in cloud ... Clarity Intelligence Platform (CIP) into Cielo®, a discovery, migration and cloud orchestration engine. ... their small and medium business (SMB) clients. , In recent years, ...
    (Date:2/12/2016)... ... February 12, 2016 , ... The Jones Agency, a ... across eastern Texas, is launching a cooperative charity drive with the Tarrant Area Food ... more than 50,000 individuals and families in need, the Tarrant County Food Bank offers ...
    (Date:2/12/2016)... ... 12, 2016 , ... Donor Network West, the organ procurement organization that heals ... with San Ramon Regional Medical Center. Under the collaboration, the first of its kind, ... accommodate a more certain time frame for donor families for the recovery of organs. ...
    (Date:2/12/2016)... NY (PRWEB) , ... February 12, 2016 , ... ... of “Revolutionizing Cancer Care.” , The print component of “Revolutionizing Cancer ... Dallas, Pittsburgh/Cleveland, New York, Washington DC/Baltimore, and Seattle, with a circulation of approximately ...
    Breaking Medicine News(10 mins):